Drug intelligence / Profile preview

N-IP-00001

Development stage: Phase 1
Lead developer: NeoTrials
Administration: Inhalation

Overview

N-IP-00001 is an investigational drug developed by NeoTrials Pty Ltd. It is currently in Phase 1 clinical trials, with the primary focus on evaluating its safety and tolerability as an inhaled therapy in healthy volunteers. The specific mechanism of action, molecular target, therapeutic area, and modality have not been disclosed publicly as of the latest available information. The drug's development is led by NeoTrials Pty Ltd, which serves as both the originator and active organization for this compound[1].

Beyond the preview

Go deeper on N-IP-00001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-IP-00001.

Explore the full profile